Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07016750
PHASE3

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Sponsor: Krystal Biotech, Inc.

View on ClinicalTrials.gov

Summary

KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).

Official title: A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

Key Details

Gender

All

Age Range

6 Months - Any

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2025-06-20

Completion Date

2026-12

Last Updated

2026-03-12

Healthy Volunteers

No

Interventions

BIOLOGICAL

KB803

Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein

DRUG

Placebo

Vehicle

Locations (5)

Mission Dermatology Center

Rancho Santa Margarita, California, United States

Skin Research Institute

Coral Gables, Florida, United States

UMass Memorial Medical Center

Worcester, Massachusetts, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States